Sign In
Buy CDIO
$2.15
-0.200 (-8.51%)
At Close: Jun 03, 2026
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its HeartRisk and Actionable Clinical Intelligence platforms at the ACC's 73rd Annual Scientific Session.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced the issuance of its second U.S. patent.
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
08:46am, Thursday, 15'th Feb 2024
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' AI-driven epigenetic-genetic blood tests will be available Q2 2024 inside the Walmart Supercenter in Round Lake Beach, Illinois.
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests
08:31am, Monday, 05'th Feb 2024
CHICAGO--(BUSINESS WIRE)--resTOR Longevity Clinic will offer Cardio Diagnostics' blood-based epigenetic-genetic cardiovascular disease tests.
Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor
08:31am, Wednesday, 24'th Jan 2024
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor.
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
08:31am, Monday, 08'th Jan 2024
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that India's Patent Office has granted a patent to the University of Iowa Research Foundation under patent number 484488.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.
Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
08:31am, Thursday, 04'th Jan 2024
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.
CHICAGO--(BUSINESS WIRE)--The AMA has granted and assigned Cardio Diagnostics a dedicated CPT® PLA for the company's AI-driven CHD event risk assessment test, Epi+Gen CHD.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that the AMA has assigned a dedicated CCPT® PLA) for the company's AI-driven CHD detection test, PrecisionCHD.
Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement
08:31am, Wednesday, 06'th Dec 2023
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced it has regained Nasdaq minimum bid price requirement.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the AMA CPT Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes.
